Abstract：OBJECTIVE To provide reference for clinical use of cenegermin eye drops by reviewing its pharmacological properties, efficacy and limitations in neurotrophic keratitis (NK). METHODS The pharmacological properties of cenegermin eye drops,its efficacy and limitations in NK were reviewed by consulting domestic and foreign literature. RESULTS Cenegermin is a recombinant human nerve growth factor (rhNGF),with the same structure as endogenous nerve growth factor. It can promote corneal wound healing,increase tear production and conjunctival goblet cell density, and support corneal nerve regeneration. Clinical registry trials have proved that cenegemin eye drops can effectively cure NK. After 8 weeks of drug treatment, compared with the control vehicle, cenegimine eye drops had significant advantages in promoting corneal healing, the recurrence rate was low, and the patients avoided the consequence of corneal blind, lysis, perforation and enucleation. In post-marketing clinical trial, after one duration of treatment of 8 weeks, cenegermin eye drops significantly repaired corneal nerve plexus and regressed the corneal neovascularization,with corneal sensitivity and visual acuity improvement. Cenegermin eye drops can be used for treatment in pediatric patients with neurotrophic keratopathy. The most obvious adverse reactions of the drug are eye discomfort. These adverse reactions are relatively mild, transient and tolerable, and have no adverse effects on the treatment. CONCLUSION As an orphan drug for NK, cenegemin eye drops is successfully marketed in China in 2021 for the treatment of moderate and severe NK in adults. Its real world treatment efficacy in China is being collected and will be published in the future.
SHEHA H, TIGHE S, HASHEM O, et al. Update on cenegermin eye drops in the treatment of neurotrophic keratitis[J]. Clin Ophthalmol, 2019, 13:1973-1980.
[2]
DEEKS E D, LAMB Y N. Cenegermin: a review in neurotrophic keratitis[J]. Drugs, 2020, 80(5):489-494.
[3]
Oxervate: EPAR-Produce information[EB/OL]. European medicines agency, 2017 [2017-07-25]. https://www.ema.europa.eu/en/medicines/human/EPAR/oxervate.
[4]
LAMBIASE A, TIRASSA P, MICERA A, et al. Pharmacokinetics of conjunctivally applied nerve growth factor in the retina and optic nerve of adult rats[J]. Invest Ophthalmol Vis Sci, 2005, 46(10):3800-3806.
[5]
FERRARI M P, MANTELLI F, SACCHETTI M, et al. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial[J]. Bio Drugs, 2014,28(3):275-283.
[6]
BONINI S, LAMBIASE A, RAMA P, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis[J]. Ophthalmology, 2018, 125(9):1332-1343.
[7]
BREMOND-GIGNAC D, DARUICH A, ROBERT M P, et al. Recent innovations with drugs in clinical trials for neurotrophic keratitis and refractory corneal ulcers[J]. Expert Opin Investig Drugs, 2019, 28(11):1013-1020.
[8]
KERATOLOGY GROUP OF OPHTHALMOLOGY BRANCH OF CHINESE MEDICAL ASSOCIATION. Consensus of experts on diagnosis and treatment of neurotrophic keratitis in China (2021)[J]. Chin J Ophthalmol(中华眼科杂志), 2021, 57(2):90-94.
[9]
DUA H S, SAID D G, MESSMER E M, et al. Neurotrophic keratopathy[J]. Prog Retin Eye Res, 2018, 66:107-131.
[10]
DOHLMAN T H, SINGH R B, DANA R. Advances in the medical management of neurotrophic keratitis[J]. Semin Ophthalmol, 2021, 36(4):335-340.
[11]
DI Z A, COASSIN M, VARACALLI G, et al. Neurotrophic keratopathy: pros and cons of current treatments[J]. Ocul Surf, 2019, 17(4):619-623.
[12]
UHLIG C E, FRINGS C, ROHLOFF N, et al. Long-term efficacy of glycerine-processed amniotic membrane transplantation in patients with corneal ulcer[J]. Acta Ophthalmol, 2015, 93(6):e481-e487.
[13]
SAMMIE E F, KATHRYN S P, BRIAN M F, et al. Impact of neurotrophic keratopathy on quality of life: a utility study[J]. Invest Ophthalmol Vis Sci, 2021, 62(8):741.
[14]
PFLUGFELDER S C, MASSARO-GIORDANO M, PEREZ V L, et al. Topical recombinant human nerve growth factor (cenegermin) for neurotrophic keratopathy: a multicenter randomized vehicle-controlled pivotal trial[J]. Ophthalmology, 2020, 127(1):14-26.
[15]
MASTROPASQUA L, LANZINI M, DUA H S, et al. In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy[J]. Am J Ophthalmol, 2020, 217:278-286.
[16]
ZWINGEBERG S B, BACHMANN B O, CURSIEFEN C. Real life data on efficacy and safety of topical NGF eye drops (cenegermin)[J]. Klin Monbl Augenheilkd, 2020, 237(12):1455-1461.
[17]
SARICAY L Y, BAYRAKTUTAR B, LILLEY J, et al. Efficacy and tolerability of cenegermin for stage 1 neurotrophic keratopathy[J]. Invest Ophthalmol Vis Sci, 2020, 61(7):374.
[18]
HSTCHER J B, SOIFER M, MORALES N G, et al. Aftermarket effects of cenegermin for neurotrophic keratopathy in pediatric patients[J]. Ocul Surf, 2021, 21:52-57.
[19]
PEDROTTI E, BONETTO J, COZZINI T, et al. Cenegermin in pediatric neurotrophic keratopathy[J]. Cornea, 2019, 38(11):1450-1452.
[20]
FAUSTO R, CECCUZZI R, MICHELETTI E, et al. A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye drops[J]. Medicine (Baltim), 2020, 99(30):e20816.
[21]
LETO M G, TORO M E, INDEMINI P E, et al. Pediatric use of recombinant human nerve growth factor 20 μg/mL eye drops (cenegermin) for bilateral neurotrophic keratopathy in congenital corneal anesthesia[J]. Cornea, 2021, 40(2):228-231.
[22]
PAPADPPOULOS K, BEGEN V, SEKUNDO W. Successful treatment of a pediatric neurotrophic keratopathy with cenegermin[J]. Cornea, 2021, 40(4):516-518.
[23]
ALICE B, MARATA S, ANTONIETTA M, et al. The long-term clinical efficacy of recombinant human nerve growth factor in the treatment of neurotrophic keratitis[J]. Invest Ophthalmol Vis Sci, 2021, 62(8):728.
[24]
WEINLANDER E, LING J, REDDY A, et al. Epithelial plaque formation secondary to recombinant human nerve growth factor[J]. Cornea, 2020, 39(9):1174-1176.
2021, Vol. 56 
